| Literature DB >> 23977142 |
Ali Rihani1, Tom Van Maerken, Filip Pattyn, Gert Van Peer, Anneleen Beckers, Sara De Brouwer, Candy Kumps, Evelien Mets, Joni Van der Meulen, Pieter Rondou, Carina Leonelli, Pieter Mestdagh, Frank Speleman, Jo Vandesompele.
Abstract
BACKGROUND: Measuring messenger RNA (mRNA) levels using the reverse transcription quantitative polymerase chain reaction (RT-qPCR) is common practice in many laboratories. A specific set of mRNAs as internal control reference genes is considered as the preferred strategy to normalize RT-qPCR data. Proper selection of reference genes is a critical issue, especially in cancer cells that are subjected to different in vitro manipulations. These manipulations may result in dramatic alterations in gene expression levels, even of assumed reference genes. In this study, we evaluated the expression levels of 11 commonly used reference genes as internal controls for normalization of 19 experiments that include neuroblastoma, T-ALL, melanoma, breast cancer, non small cell lung cancer (NSCL), acute myeloid leukemia (AML), prostate cancer, colorectal cancer, and cervical cancer cell lines subjected to various perturbations.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23977142 PMCID: PMC3743747 DOI: 10.1371/journal.pone.0071776
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Various treatments of neuroblastoma cells.
(A), nutlin-3 treated NGP cells, 16 µM (right) and vehicle control (left). (B), ATRA treated NGP cells with elongated neurites (right) and vehicle control (left). (C), cell viability assay of IMR-32 and SK-N-SH cells after treatment with increasing concentrations of withaferin-A for 24 hours. Error bars, SD (n = 3). (D), cell viability assay after treatment of CLB-GA and SK-N-SH cells with increasing concentrations of TAE-684 for 24 hours. Error bars, SD (n = 3). (E), RT-qPCR expression data of PTK9 in SH-EP, SK-N-SH, SH-SY5Y and SK-N-BE(2c) after transfection with miR-1 mimic or scrambled miRNA mimic serving as a negative control (NC). Error bars, SEM (n = 2). (F), RT-qPCR expression data of T-UCR uc. 73 (left) and T-UCR uc.460 (right) 24 hours after transfection of SH-EP cells with siRNA against T-UCR uc. 73 and siRNA against T-UCR uc. 460 respectively. Errors bars, SEM (n = 2).
Figure 2RT-qPCR expression data of PHF6 in T-ALL cell line.
JURKAT cell line after transfection of PHF6-targeting siRNA or scrambled siRNA (negative control: NC). Error bars, SEM (n = 2).
Figure 3Average expression stability values of the reference genes.
X-axis shows the ranking of reference genes, and Y-axis shows geNorm M-values. (A), nutlin-3 treated neuroblastoma cells. (B), ATRA treated neuroblastoma cells. (C), withaferin A treated neuroblastoma cells. (D), TAE-684 treated neuroblastoma cells. (E), neuroblastoma cells transfected with siRNAs against T-UCRs. (F), neuroblastoma cells transfected with miR-1 mimic. (G), T-ALL cell lines (HPB-ALL, ALL-SIL, and TALL-1) transfected with miR-223 mimic or negative control miR mimic. (H), T-ALL cell line JURKAT transfected with PHF6-targeting siRNA or negative control siRNA. (I), T-ALL cell lines (HSB-2 and PF-382) transfected with PHF6-targeting siRNA or negative control siRNA. (J), NSCL cell line (H3122) treated with crizotinib. (K), melanoma cell line (WM-9) transfected with siRNA against Cyclophilin-B. (L), AML cell line (K562) treated with JQ1. (M), breast cancer cell line (MCF-7) treated with JQ1. (N), breast cancer cell line (SKBR-3) treated with JQ1. (O), prostate cancer cell line (PC-3) treated with JQ1. (P), colorectal cell line (SW-620) treated with JQ1. (Q), neuroblastoma cell line (SJNB-12) treated with JQ1. (R), MCF-7 treated with 90 different chemical inhibitors. (S), cervical cancer cell line (HeLa) treated with 90 different chemical inhibitors.
Figure 4Rank aggregation analysis.
Rank aggregation result using the cross entropy algorithm with spearman’s foot-rule weighted distance which shows a consensus order of reference genes from the most stable to the least stable.
M-values for the candidate reference genes under different treatment conditions.
| S | 0.68 | 1.15 | 0.86 | 0.61 | 0.77 | 0.63 | 1.22 | 0.62 | 1.01 | 0.94 | 1.08 |
| R | 0.75 | 0.90 | 0.59 | 1.18 | 0.81 | 0.54 | 0.86 | 0.53 | 0.98 | 0.93 | 1.06 |
| Q | 0.16 | 0.47 | 0.27 | 0.14 | 0.14 | 0.21 | 0.18 | 0.23 | 0.25 | 0.28 | 0.30 |
| P | 0.05 | 0.22 | 0.12 | 0.07 | 0.04 | 0.04 | 0.06 | 0.15 | 0.10 | 0.26 | 0.17 |
| O | 0.38 | 0.33 | 0.40 | 0.11 | 0.12 | 0.16 | 0.36 | 0.21 | 0.26 | 0.30 | 0.13 |
| N | 0.14 | 0.41 | 0.46 | 0.33 | 0.30 | 0.13 | 0.13 | 0.43 | 0.36 | 0.51 | 0.39 |
| M | 0.06 | 0.26 | 0.25 | 0.14 | 0.08 | 0.11 | 0.08 | 0.29 | 0.18 | 0.23 | 0.21 |
| L | 0.14 | 0.38 | 0.32 | 0.12 | 0.08 | 0.20 | 0.09 | 0.10 | 0.25 | 0.45 | 0.28 |
| K | 0.08 | 0.14 | 0.12 | 0.08 | 0.08 | 0.10 | 0.13 | 0.10 | 0.17 | 0.12 | 0.11 |
| J | 0.22 | 0.34 | 0.38 | 0.27 | 0.26 | 0.46 | 0.22 | 0.51 | 0.28 | 0.41 | 0.54 |
| I | 0.62 | 0.64 | 0.75 | 0.98 | 0.59 | 0.63 | 0.55 | 0.82 | 0.67 | 0.57 | 1.35 |
| H | 0.15 | 0.15 | 0.16 | 0.19 | 0.41 | 0.31 | 0.29 | 0.22 | 0.27 | 0.33 | 0.21 |
| G | 0.59 | 0.80 | 0.61 | 0.56 | 1.10 | 0.88 | 0.83 | 0.99 | 1.98 | 1.42 | 1.66 |
| F | 0.33 | 0.32 | 0.32 | 0.45 | 0.56 | 0.65 | 0.39 | 0.84 | 1.29 | 1.48 | 1.07 |
| E | 0.48 | 0.58 | 0.77 | 1.11 | 0.46 | 0.47 | 0.54 | 0.85 | 0.64 | 1.35 | 0.90 |
| D | 0.42 | 0.28 | 0.52 | 0.27 | 0.30 | 0.34 | 0.65 | 0.70 | 0.29 | 0.58 | 0.48 |
| C | 0.37 | 0.34 | 0.65 | 0.38 | 0.41 | 0.70 | 1.04 | 0.61 | 0.77 | 0.52 | 0.84 |
| B | 0.47 | 0.50 | 0.29 | 0.39 | 0.63 | 0.56 | 0.53 | 0.28 | 0.45 | 0.31 | 0.88 |
| A | 0.61 | 0.60 | 0.93 | 0.69 | 0.64 | 0.61 | 0.79 | 1.11 | 0.87 | 0.99 | 1.20 |
| Alu-Sq | TBP | HPRT1 | YWHAZ | GAPDH | SDHA | HMBS | B2M | UBC | ACTB | RPL13A |
This table shows the 19 ordered lists of 11 reference candidates with their corresponding M-values. These M-values were used to rank the 11 reference candidates within each ordered list (in columns).
(A), nutlin-3 treated neuroblastoma cells. (B), ATRA treated neuroblastoma cells. (C), withaferin A treated neuroblastoma cells. (D), TAE-684 treated neuroblastoma cells. (E), neuroblastoma cells transfected with siRNAs against T-UCRs. (F), neuroblastoma cells transfected with miR-1 mimic. (G), T-ALL cell lines (HPB-ALL, ALL-SIL, and TALL-1) transfected with miR-223 mimic or negative control miRNA mimic. (H), T-ALL cell line JURKAT transfected with PHF6-targeting siRNA or negative control siRNA. (I), T-ALL cell lines (HSB-2 and PF-382) transfected with PHF6-targeting siRNA or negative control siRNA. (J), NSCL cell line (H3122) treated with crizotinib. (K), melanoma cell line (WM-9) transfected with siRNA against cyclophilin-B. (L), AML cell line (K562) treated with JQ1. (M), breast cancer cell line (MCF-7) treated with JQ1. (N), breast cancer cell line (SKBR-3) treated with JQ1. (O), prostate cancer cell line (PC-3) treated with JQ1. (P), colorectal cancer cell line (SW-620) treated with JQ1. (Q), neuroblastoma cell line (SJNB-12) treated with JQ1. (R), MCF-7 cells treated with 90 different chemical inhibitors. (S), cervical cancer cell line (HeLa) treated with 90 different chemical inhibitors.